Related Experiment Video
Updated: Jun 21, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective cohort study
Ignacio Cruz-González1, Esther Corral, María Sánchez-Ledesma
1Cardiology Department, University Hospital of Salamanca, Salamanca, Spain. cruzgonzalez.ignacio@gmail.com
BMC Cardiovascular Disorders
|August 5, 2009
Summary
The -786CC genotype of the endothelial nitric oxide synthase (NOS3) gene is linked to an increased risk of resistant hypertension. This finding suggests a potential endothelial basis for resistance to blood pressure medications.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Pharmacogenomics
Background:
- Resistant hypertension affects approximately 5% of hypertensive patients.
- Endothelial nitric oxide synthase (NOS3) gene polymorphisms are linked to blood pressure but not resistant hypertension.
- Investigating NOS3 gene variants in resistant hypertension is crucial for understanding treatment resistance.
Purpose of the Study:
- To determine the association between NOS3 gene polymorphisms (-786T>C and G894T) and resistant hypertension.
- To explore the role of endothelial function in the development of resistant hypertension.
Main Methods:
- A prospective case-control observational study.
- Inclusion of 48 patients with resistant hypertension and 232 patients with controlled hypertension.
- Analysis of -786T>C and G894T (Glu298Asp) polymorphisms in the NOS3 gene.
Main Results:
- No significant difference in G894T (Glu298Asp) genotype distribution between groups.
- The -786CC genotype was significantly more frequent in patients with resistant hypertension (33.3%) compared to controlled hypertension (17.7%) (p=0.03).
- Carriers of the -786T allele were more prevalent in the controlled hypertension group (82.3%) versus the resistant hypertension group (66.7%) (RR 2.09; p=0.004).
Conclusions:
- The -786CC genotype of the NOS3 gene is associated with an increased susceptibility to resistant hypertension.
- Endothelial dysfunction may play a role in the development of resistance to antihypertensive therapy.
- These findings highlight the potential of genetic markers in predicting treatment response.
Related Concept Videos
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...